SWAV vs. PODD, SOLV, TFX, PEN, INSP, GMED, GKOS, MMSI, HAE, and BAX
Should you be buying Shockwave Medical stock or one of its competitors? The main competitors of Shockwave Medical include Insulet (PODD), NYSE:SOLV (SOLV), Teleflex (TFX), Penumbra (PEN), Inspire Medical Systems (INSP), Globus Medical (GMED), Glaukos (GKOS), Merit Medical Systems (MMSI), Haemonetics (HAE), and Baxter International (BAX). These companies are all part of the "medical" sector.
Insulet (NASDAQ:PODD) and Shockwave Medical (NASDAQ:SWAV) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
95.4% of Shockwave Medical shares are held by institutional investors. 0.8% of Insulet shares are held by company insiders. Comparatively, 3.4% of Shockwave Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Insulet currently has a consensus target price of $243.21, indicating a potential upside of 45.42%. Shockwave Medical has a consensus target price of $309.11, indicating a potential downside of 6.01%. Given Shockwave Medical's stronger consensus rating and higher possible upside, analysts clearly believe Insulet is more favorable than Shockwave Medical.
Insulet received 574 more outperform votes than Shockwave Medical when rated by MarketBeat users. Likewise, 65.98% of users gave Insulet an outperform vote while only 55.83% of users gave Shockwave Medical an outperform vote.
Insulet has higher revenue and earnings than Shockwave Medical. Insulet is trading at a lower price-to-earnings ratio than Shockwave Medical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Shockwave Medical had 8 more articles in the media than Insulet. MarketBeat recorded 11 mentions for Shockwave Medical and 3 mentions for Insulet. Shockwave Medical's average media sentiment score of 1.33 beat Insulet's score of 0.81 indicating that Insulet is being referred to more favorably in the media.
Shockwave Medical has a net margin of 20.17% compared to Shockwave Medical's net margin of 12.16%. Shockwave Medical's return on equity of 32.19% beat Insulet's return on equity.
Insulet has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Shockwave Medical has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
Summary
Insulet beats Shockwave Medical on 10 of the 18 factors compared between the two stocks.
Get Shockwave Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWAV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SWAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shockwave Medical Competitors List
Related Companies and Tools
